HilleVax, Inc. (HLVX)
NASDAQ: HLVX · IEX Real-Time Price · USD
1.770
-0.090 (-4.84%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Company Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.
It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021.
HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
HilleVax, Inc.
Country | United States |
Founded | 2020 |
IPO Date | Apr 29, 2022 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 90 |
CEO | Dr. Robert M. Hershberg M.D., Ph.D. |
Contact Details
Address: 321 Harrison Ave, Suite 500 Boston, Massachusetts 02118 United States | |
Phone | (617) 213-5054 |
Website | hillevax.com |
Stock Details
Ticker Symbol | HLVX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $17.00 |
CIK Code | 0001888012 |
CUSIP Number | 43157M102 |
ISIN Number | US43157M1027 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Robert M. Hershberg M.D., Ph.D. | President, Chief Executive Officer and Chairman of the Board |
Dr. Aditya Kohli Ph.D. | Chief Business Officer and Director |
Shane A. Maltbie | Chief Financial Officer and Treasurer |
Sean McLoughlin | Chief Operating Officer |
Dr. Anju Chatterji Ph.D. | Chief Technology Officer |
Paul S. Bavier J.D. | General Counsel, Secretary and Chief Administrative Officer |
Astrid Borkowski M.D., Ph.D. | Chief Medical Officer |
Ozzie Berger | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 8, 2024 | 8-K | Current Report |
Jun 10, 2024 | 8-K | Current Report |
May 31, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
May 9, 2024 | EFFECT | Notice of Effectiveness |
May 9, 2024 | 10-Q | Quarterly Report |
May 9, 2024 | 8-K | Current Report |
Apr 26, 2024 | ARS | Filing |
Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |